.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Cerilliant
UBS
Queensland Health
Cantor Fitzgerald
Daiichi Sankyo
Julphar
US Department of Justice
Johnson and Johnson
Covington

Generated: December 18, 2017

DrugPatentWatch Database Preview

Eisai Inc Company Profile

« Back to Dashboard

What is the competitive landscape for EISAI INC, and what generic alternatives to EISAI INC drugs are available?

EISAI INC has seventeen approved drugs.

There are thirty-two US patents protecting EISAI INC drugs and there have been three Paragraph IV challenges on EISAI INC drugs in the past three years.

There are four hundred and eighty-seven patent family members on EISAI INC drugs in forty-eight countries and forty-six supplementary protection certificates in fifteen countries.

Summary for Eisai Inc

International Patents:487
US Patents:32
Tradenames:13
Ingredients:11
NDAs:17
Drug Master File Entries: 1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai IncBELVIQ XRlorcaserin hydrochlorideTABLET, EXTENDED RELEASE;ORAL208524-001Jul 15, 2016RXYesYes► Subscribe► SubscribeYY► Subscribe
Eisai IncBELVIQ XRlorcaserin hydrochlorideTABLET, EXTENDED RELEASE;ORAL208524-001Jul 15, 2016RXYesYes► Subscribe► SubscribeYY► Subscribe
Eisai IncFYCOMPAperampanelTABLET;ORAL202834-005Oct 22, 2012RXYesNo► Subscribe► SubscribeY► Subscribe
Eisai IncHALAVENeribulin mesylateSOLUTION;INTRAVENOUS201532-001Nov 15, 2010RXYesYes► Subscribe► Subscribe► Subscribe
Eisai IncFYCOMPAperampanelTABLET;ORAL202834-003Oct 22, 2012RXYesNo► Subscribe► Subscribe► Subscribe
Eisai IncBELVIQlorcaserin hydrochlorideTABLET;ORAL022529-001Jun 27, 2012RXYesYes► Subscribe► SubscribeYY► Subscribe
Eisai IncBELVIQlorcaserin hydrochlorideTABLET;ORAL022529-001Jun 27, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Eisai IncARICEPTdonepezil hydrochlorideTABLET;ORAL022568-001Jul 23, 2010ABRXYesYes► Subscribe► SubscribeY► Subscribe
Eisai IncBANZELrufinamideTABLET;ORAL021911-003Nov 14, 2008ABRXYesYes► Subscribe► SubscribeY► Subscribe
Eisai IncBELVIQlorcaserin hydrochlorideTABLET;ORAL022529-001Jun 27, 2012RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Eisai Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eisai IncARICEPTdonepezil hydrochlorideTABLET;ORAL020690-002Nov 25, 1996► Subscribe► Subscribe
Eisai IncARICEPTdonepezil hydrochlorideTABLET;ORAL020690-001Nov 25, 1996► Subscribe► Subscribe
Eisai IncACIPHEXrabeprazole sodiumTABLET, DELAYED RELEASE;ORAL020973-002Aug 19, 1999► Subscribe► Subscribe
Eisai IncARICEPTdonepezil hydrochlorideTABLET;ORAL020690-002Nov 25, 1996► Subscribe► Subscribe
Eisai IncPANRETINalitretinoinGEL;TOPICAL020886-001Feb 2, 1999► Subscribe► Subscribe
Eisai IncARICEPTdonepezil hydrochlorideTABLET;ORAL022568-001Jul 23, 2010► Subscribe► Subscribe
Eisai IncARICEPT ODTdonepezil hydrochlorideTABLET, ORALLY DISINTEGRATING;ORAL021720-001Oct 18, 2004► Subscribe► Subscribe
Eisai IncARICEPTdonepezil hydrochlorideTABLET;ORAL020690-002Nov 25, 1996► Subscribe► Subscribe
Eisai IncACIPHEXrabeprazole sodiumTABLET, DELAYED RELEASE;ORAL020973-002Aug 19, 1999► Subscribe► Subscribe
Eisai IncACIPHEXrabeprazole sodiumTABLET, DELAYED RELEASE;ORAL020973-001May 29, 2002► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for EISAI INC drugs

Drugname Dosage Strength Tradename Submissiondate
lorcaserin hydrochlorideExtended-release Tablets20 mgBELVIQ XR12/13/2016
perampanelTablets2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mgFYCOMPA10/24/2016
lorcaserin hydrochlorideTablets10 mgBELVIQ6/27/2016
rufinamideOral Suspension40 mg/mLBANZEL6/16/2014
donepezil hydrochlorideTablets23 mgARICEPT7/9/2013
rufinamideTablets100 mg, 200 mg and 400 mgBANZEL11/14/2012
donepezil hydrochlorideOrally Disintegrating Tablets5 mg and 10 mgARICEPT ODT6/30/2010

Premature patent expirations for EISAI INC

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

Non-Orange Book Patents for Eisai Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,304,548Method for producing 1, 2-dihydropyridine-2-one compound► Subscribe
9,045,426Method for producing 1,2-dihydropyridine-2-one compound► Subscribe
8,148,554Methods and compositions for use in treating cancer► Subscribe
7,939,5491,2-dihydropyridine compounds, manufacturing method thereof and use thereof► Subscribe
7,704,993Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases► Subscribe
8,372,981Nitrogen-containing aromatic derivatives► Subscribe
9,102,627Processes for preparing 3-benzazepines► Subscribe
7,056,954Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor► Subscribe
6,653,341 Methods and compositions for use in treating cancer► Subscribe
5,968,989 Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Eisai Inc Drugs

Country Document Number Estimated Expiration
South Africa200705125► Subscribe
European Patent Office1698623► Subscribe
Portugal1411881► Subscribe
Russian Federation2245335► Subscribe
China1357000► Subscribe
South Africa200007159► Subscribe
Austria547405► Subscribe
Australia2004309217► Subscribe
South Korea20070094994► Subscribe
South Korea100904011► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Eisai Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0566Netherlands► SubscribePRODUCT NAME: PERAMPANEL, EEN ZOUT OF EEN HYDRAAT DAARVAN; REGISTRATION NO/DATE: EU/1/12/776/001 .... 016 20120723
/2011Austria► SubscribePRODUCT NAME: ERIBULIN UND PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; REGISTRATION NO/DATE: EU/1/11/678/001-002 20110317
90045-2Sweden► SubscribePRODUCT NAME: PERAMPANEL OCH SALTER OCH HYDRATER DAERAV; REG. NO/DATE: EU/1/12/776/001 20120723
1300396/01Switzerland► SubscribePRODUCT NAME: PERAMPANEL; REGISTRATION NO/DATE: SWISSMEDIC 62440 14.12.2012
1 5023-2015Slovakia► SubscribePRODUCT NAME: LENVATINIB MESYLAT; REGISTRATION NO/DATE: EU/1/15/1002/001 - EU/1/15/1002/002 20150601
01/009Ireland► SubscribePRODUCT NAME: PANRETIN-ALITRETINOIN
1087960/01Switzerland► SubscribePRODUCT NAME: ERIBULIN; REGISTRATION NO/DATE: SWISSMEDIC 59489 20110513
C0070France► SubscribePRODUCT NAME: LENVATINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI OU UN HYDRATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/15/1002 20150601
0764Netherlands► SubscribePRODUCT NAME: LENVATINIB, EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, OF EEN HYDRAAT DAARVAN; REGISTRATION NO/DATE: EU/1/15/1002/001 -002 20150528
00493Netherlands► SubscribePRODUCT NAME: ERIBULIN, ALSMEDE FARMACEUTISCHE ZOUTEN ERVAN, IN HET BIJZONDER HET MESYLAAT; REGISTRATION NO/DATE: EU/1/11/678/001-002 20110317
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Moodys
Cipla
Express Scripts
Julphar
US Army
Covington
McKinsey
Harvard Business School
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot